glp-1 psoriatic arthritis receptor agonists: emerging therapeutic potential in psoriasis management — current evidence and future outlook | European Journal of Clinical Pharmacology Glucagon-like peptide-1 receptor agonists in

A widely used GLP-1 drug may do more than treat obesity and diabetes

Always obtain FAA clearance before starting any new medication

read more Achieving glucose goals is a critical part of overall diabetes management

Observational research presented in March 2026 at the American Academy of Orthopaedic Surgeons annual meeting found that GLP-1 drugs may slightly increase the risk of developing osteoporosis and gout, a kind of inflammatory arthritis caused by a buildup of uric acid

This is primarily due to its superior efficacy in achieving significant weight loss outcomes

Zepbound works by activating receptors for two gut hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)